Review highlights shared drug targets in Plasmodium and Babesia
Bottom line
A new review in Tropical Animal Health and Production argues that Plasmodium and Babesia should be studied more deliberately as cross-species therapeutic targets, because both parasites invade and replicate within erythrocytes and appear to share vulnerable invasion pathways and conserved drug targets. The paper, by Mamta Tirdia, Meenu Lakhlan, and Rajender Kumar, frames this overlap as a practical opportunity for drug discovery at a time when resistance, limited treatment options, and the growing veterinary and zoonotic relevance of babesiosis are keeping pressure on both animal and human health systems. Supporting literature cited in the broader field shows that blood-stage Plasmodium and Babesia can share chemosensitivity to some compound classes, while newer studies have also identified both parasite-specific and broad-spectrum activity among red-blood-cell-targeting molecules. (pubmed.ncbi.nlm.nih.gov)
Why it matters: For veterinary professionals, the review reinforces a useful translational idea: advances in malaria biology may help accelerate therapies for babesiosis, especially where conserved pathways such as erythrocyte invasion signaling, mitochondrial cytochrome bc1, folate metabolism, and other apicomplexan survival mechanisms are involved. That matters because babesiosis remains economically important in livestock, clinically relevant in dogs and other animals, and increasingly notable as a zoonosis, while resistance concerns continue to shape antiparasitic development. Prior studies have shown promising cross-parasite activity in compounds targeting conserved pathways, including cytochrome bc1 inhibitors and next-generation screening hits tested across Babesia and Plasmodium species. (journals.asm.org)
What to watch: Expect follow-up work to focus less on broad conceptual overlap and more on which conserved targets can translate into safe, species-specific, resistance-aware therapies for veterinary babesiosis. (journals.asm.org)
Key facts
- Article type
- Review
- Journal
- Tropical Animal Health and Production
- Main topic
- Cross-species therapeutic targets in Plasmodium and Babesia
- Shared biology
- Both parasites invade and replicate within erythrocytes
- Therapeutic rationale
- They may share vulnerable invasion pathways and conserved drug targets
- Key concern
- Resistance and limited treatment options
- Veterinary relevance
- Babesiosis is clinically relevant in dogs and other animals, and economically important in livestock
- Zoonotic relevance
- Babesiosis is increasingly notable as a zoonosis
A new review in Tropical Animal Health and Production highlights a familiar but still underused idea in parasite pharmacology: the blood-stage biology of Plasmodium and Babesia may offer shared therapeutic openings. The authors argue that because both genera occupy the same erythrocyte niche, researchers may be able to exploit conserved invasion machinery and drug-sensitive pathways to support cross-species therapeutic development, particularly as resistance and limited treatment options remain persistent concerns. That framing fits with a growing body of literature pointing to overlap in how these apicomplexan parasites invade red blood cells, persist intracellularly, and respond to at least some common compound classes. (pmc.ncbi.nlm.nih.gov)
The background here is important. Malaria research has long outpaced babesiosis research in scale, funding, and drug-development infrastructure, which means veterinary and zoonotic babesiosis often benefit indirectly when malaria biology reveals a conserved mechanism worth testing elsewhere. Reviews and primary studies over the past decade have repeatedly pointed to common themes across erythrocytic parasites, including shared dependence on host-cell interactions, conserved metabolic vulnerabilities, and recurring pressure from drug resistance. At the same time, Babesia is not simply a malaria analog: its intracellular development differs in meaningful ways, and those differences can limit how directly malaria discoveries translate into veterinary use. (pmc.ncbi.nlm.nih.gov)
That tension, shared biology but incomplete interchangeability, is what makes this review useful. Earlier screening work found extensive shared chemosensitivity between blood-stage malaria and babesiosis parasites, suggesting that some conserved targets are pharmacologically actionable across genera. More recent work has sharpened that idea by showing that red-blood-cell-targeting small molecules can produce Plasmodium-specific, Babesia-specific, or broad-spectrum antiparasitic effects, which suggests the host cell itself may also be part of the therapeutic opportunity. (pubmed.ncbi.nlm.nih.gov)
Several target classes help explain why this cross-species approach keeps attracting attention. Cytochrome bc1 remains one of the clearest examples of a conserved apicomplexan vulnerability, with published data supporting efficacy of endochin-like quinolones and related approaches in Babesia models, while the same pathway has long been relevant in malaria therapeutics. Other recent work has evaluated next-generation dihydrotriazines and biguanides across multiple Babesia isolates and Plasmodium falciparum, again underscoring the value of comparative screening. Broader 2026 review literature has also emphasized coenzyme A and polyamine biosynthesis as promising metabolic targets across hemoparasites, including Plasmodium and Babesia. (journals.asm.org)
On the invasion side, malaria research continues to generate mechanistic insights that could influence future babesiosis drug design. Foundational studies established essential host-parasite interactions in erythrocyte invasion, including receptor-ligand dependencies in P. falciparum. More recent structural work in malaria has drawn attention to highly conserved invasion machinery and proof-of-concept invasion-blocking designs, although applying those insights directly to Babesia will require validation rather than assumption. That’s an inference from the available literature, not a settled conclusion, but it’s exactly the kind of translational bridge this review is encouraging the field to test. (pubmed.ncbi.nlm.nih.gov)
Expert reaction specific to this review was limited in publicly indexed sources, but the surrounding literature shows a clear industry and research direction: move beyond one-pathogen drug discovery and look for conserved, resistance-aware targets across related erythrocytic parasites. That includes host-directed strategies, comparative screening platforms, and attention to resistance mechanisms such as mutations affecting mitochondrial or folate-pathway targets. The veterinary relevance is especially strong where babesiosis imposes clinical burden in companion animals and economic losses in livestock, yet still lacks the depth of therapeutic innovation seen in malaria. (frontiersin.org)
Why it matters: For veterinary professionals, the review is less about an immediate practice change and more about where the pipeline may be heading. If conserved invasion pathways or metabolic targets can be validated across genera, veterinary medicine could benefit from a more efficient discovery model, one that borrows from malaria science without ignoring species-specific biology, safety, residue, and resistance realities. That could eventually matter for companion-animal babesiosis, food-animal production, and zoonotic risk management alike. (pmc.ncbi.nlm.nih.gov)
What to watch: The next step is likely comparative preclinical work that tests which shared targets truly hold up across Babesia species of veterinary importance, and whether any candidate compounds can balance efficacy, safety, and resistance durability well enough to move toward field-relevant development. (journals.asm.org)